Targeted Nanoparticles for Glioblastoma Brain Tumors
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
This project is developing tiny, targeted particles to deliver medicine directly to brain tumor cells, aiming to help people with glioblastoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanovalent Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Bozeman, United States) |
| Project ID | NIH-11145974 on NIH RePORTER |
What this research studies
Glioblastoma (GBM) is a very aggressive brain tumor that is difficult to treat because most medicines cannot cross the protective blood-brain barrier. This project is creating special nanoparticles designed to overcome this barrier and specifically target human brain tumor cells. Once inside the tumor cells, these nanoparticles release powerful anti-cancer drugs, working to kill the cancer cells and potentially shrink the tumor. The ultimate goal is to find a new way to treat these challenging brain tumors and improve patient outcomes.
Who could benefit from this research
Good fit: This research is focused on adults with glioblastoma multiforme (GBM) and other intractable brain tumors.
Not a fit: Patients with non-brain tumors or those whose tumors do not express the specific antigens targeted by these nanoparticles may not benefit from this particular treatment.
Why it matters
Potential benefit: If successful, this approach could offer a new way to treat aggressive brain tumors like glioblastoma, potentially extending survival and improving outcomes.
How similar studies have performed: This approach uses a novel method to overcome the blood-brain barrier, a challenge that has limited the success of traditional cancer treatments for brain tumors.
Where this research is happening
Bozeman, United States
- Nanovalent Pharmaceuticals, INC. — Bozeman, United States (Active)
Researchers
- Principal investigator: Nagy, Jon Owen — Nanovalent Pharmaceuticals, INC.
- Study coordinator: Nagy, Jon Owen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.